• 1
    Barandun S, Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 1986; 51:15760.
  • 2
    Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991; 325:1107.
  • 3
    Ballow M, ed. IVIG therapy today. Totowa, NJ: Humana Press, 1992.
  • 4
    Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc 2002; 42:44959.
  • 5
    Anonymous. Outbreak of hepatitis C associated with intravenous immunoglobulin administration – United States, October 1993–June 1994. MMWR 1994; 43:5059.
  • 6
    Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331:160711.
  • 7
    Bresee JS, Ee M, Coleman PJ et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. JAMA 1996; 276:15637.
  • 8
    Ballow M. Safety of IVIG therapy and infusion-related adverse events. Immunol Res 2007; 38:12232.
  • 9
    Johnson RT, Gibbs CJ Jr. Creutzfeldt–Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:19942004.
  • 10
    Brown P. Can Creutzfeldt–Jakob disease be transmitted by transfusion? Curr Opin Hematol 1995; 2:4727.
  • 11
    Berger M. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma®. J Clin Immunol 2007; 27:62833.
  • 12
    Lopez M, Ristol P, Jorquera J. Characterisation of a new intravenous immunoglobulin. J Allergy Clin Immunol 2007; 119:S2623.
  • 13
    Biescas H, Caballero S, Domingo N, Gajardo R, Jorquera J. Viral safety studies of a new human intravenous immunoglobulin (IVIG31). J Allergy Clin Immunol 2007; 119:S264.
  • 14
    Díez J, Biescas H, Caballero S, Gajardo R, Jorquera J. Capacity of human intravenous immunoglobulin (IVIG31) production process to eliminate an experimental TSE-model agent. J Allergy Clin Immunol 2007; 119:S263.
  • 15
    Berger M, Cunningham-Rundles C, Bonilla FA et al. Carimune NF liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol 2007; 27:5039.
  • 16
    Church JS, Leibl H, Stein MR et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [(IVIG 10%] in patients with primary immunodeficiency. J Clin Immunol 2006; 26:38895.
  • 17
    Ochs HD, Pinciaro PJ. Octagam®5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004; 24:30914.